Transdermal delivery of hormones with low concentration of penetration enhancers

US9005653B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Thomas Langguth · Jena, DE
• Stefan Bracht · Hohen Neuendorf, DE
• Michael Dittgen · Apolda, DE
• Petra Huber · Munich, DE
• Dirk Schenk · Dietramszell, DE

Key dates

• Filing date: Dec 27, 2013
• Grant date: Apr 14, 2015
• Expiry date: Dec 27, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/57
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.